Press Releases

 2010

Date Title
07/28 Bioject to Report Second Quarter 2010 Financial Results
07/08 Bioject’s Intradermal Needle-Free Delivery System Used in World Health Organization Clinical Trial in Oman with Poliovirus Vaccine
06/10 2010 Annual Meeting of Shareholders (Audio)
06/04 Bioject Medical Technologies Inc. Annual Shareholder Meeting Thursday, June 10, 2010
05/13 Bioject Reports First Quarter 2010 Financial Results (Audio)
05/12 Bioject Reports First Quarter 2010 Financial Results
05/05 Bioject to Report First Quarter 2010 Financial Results
04/28 Bioject Announces Results of Intradermal Dose Sparing Influenza Study Conducted by the Centers for Disease Control and Prevention
04/27 Bioject Announces Results from US Navy Study for a Malaria Vaccine
04/26 2009 Annual Report
04/26 2010 Proxy
04/07 Bioject Meets Final Development Milestone for Merial Ltd
03/17 Bioject Reports December 31, 2009 Results
02/22 Cyto Pulse, the Karolinska Institute and the Swedish Institute for Infectious Disease Control Receive Phase I Clinical Trial Approval from the Swedish Medical Products Agency to Evaluate an HIV Vaccine in Healthy Volunteers
02/16 MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine
01/05 Bioject Establishes Strategic Alliance with MPI Research

 

 

  2009

Date Title
12/21 Bioject Closes Previously Announced Equity Financing
11/05 Bioject Reports Third Quarter 2009 Results (Audio)
11/04 Bioject Reports Third Quarter 2009 Results
10/30 Bioject to Report Third Quarter 2009 Financial Results
08/06 Bioject Reports Second-Quarter 2009 Financial Results (Audio)
08/05 Bioject Reports Second-Quarter 2009 Financial Results
05/06 Bioject Reports First Quarter 2009 Financial Results
05/05 Bioject Signs CRADA with US Navy to Study a Malaria Vaccine
04/14 Bioject Meets Milestone for Merial Limited
04/06 Bioject Announces FDA Market Clearance for the Zetajet™ Needle-Free Injection Therapy System
03/27 Fourth Quarter and Year-End 2008 Financial Results (Audio)
03/25 Bioject Reports December 31, 2008 Results
02/24 Bioject Enters into a Collaborative Research Agreement with IAVI for the Delivery of an HIV Vaccine Candidate
02/10 Bioject Extends Supply Agreement with Ferring Pharmaceuticals, Inc.

 

 | 2008

Date Title
12/09 SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
11/10 Bioject Reports Third-Quarter 2008 Results
11/06 U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
08/19 Karolinska Institutet to Test Vical’s Vaxfectin® Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
08/06 Bioject Reports Second-Quarter 2008 Financial Results
07/22 Bioject to Be Transferred to the over-the-Counter Bulletin Board
07/17 Biojector®2000 Data Presented in Vical’s Pandemic Influenza DNA Vaccine Human Trial
06/23 Bioject Announces Long-Term Agreement With Merial Limited
06/05

Bioject and ImmunoVaccine Technologies Announce Research Collaboration
05/27 Biojector®2000 Technology Put to the Test in CDC Flu Vaccine Study
05/23 Bioject Receives Nasdaq Staff Detemination
05/07 First Quarter 2008 Earnings Release
03/17 Bioject Reports December 31, 2007 Results and Initiates New Strategy